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Neurogenic inflammation encompasses a series of 
vascular and non-vascular inflammatory 
responses, triggered by the activation of primary 
sensory neurons with a subsequent release of 
inflammatory neuromediators, resulting in a 
neurally mediated immune inflammation1,2. 
Neuromediators are mainly released from 
neurons. Immune and/or structural cells are 
secondary sources of these mediators during 
immune inflammation3,4. Neuromediators include 
neurotrophins and neuropeptides4 (table 1). 
 
Table 1. Mediators of neurogenic inflammation (neuromediators)5,6. 
Neurotrophins Neuropeptides 
Nerve growth factor (NGF)  Calcitonin gene-related peptide (CGRP) 
Brain-derived neurotrophic factor (BDNF)  Vasoactive intestinal peptide (VIP) 
Neurotrophin (NT)-3   Neuropeptide Y (NPY)  
Neurotrophin-4/5  Tachykinins  (substance P, neurokinin A and  neurokinin B) 




BDNF: brain-derived neurotrophic factor; NGF: nerve growth factor;  NT:  neurotrophin. 
 
Figure 1. Signaling of neurotrophins via cell surface receptors. 
Members of the neurotrophin family bind to ligand-specific (high affinity) tropomyosine-related kinase (Trk) receptors. 
In addition, all neurotrophins bind to the common pan-neurotrophin (low affinity) receptor p75NTR. The high affinity 
receptors mediate trophic effects, whereas the low affinity receptor may be involved in induction of apoptosis. (Quoted 
from Nockher and Renz, 2006)5. 
 
Neurotrophins are protein family of neuronal 
growth factors that control the survival, 
differentiation and maintenance of neurons in the 
peripheral as well as in the central nervous system 
in the embryonic and postnatal stages7. They induce 
a variety of responses in peripheral sensory and 
sympathetic neurons. These effects include 
chemotaxis, regulation of neurotransmitter 
production and excitability, establishment of 
functional synapses and control of metabolic 
functions and peripheral axonal branching. 
Overexpression of neurotrophins in peripheral body 
tissues results in sensory hyperinnervation8. 
Neurotrophins exert their cellular effects by 
interaction with two structurally unrelated receptors 
differing in specificity for ligand and signal 




Tachykinins  have previously been considered as a 
group of neuropeptides because of their widespread 
distribution in the central and the peripheral 
nervous system (capsaicin sensitive primary 
afferent neurons and capsaicin insensitive intrinsic 
neurons). This terminology is no longer held since 
their presence in a variety of non-neuronal 
structures has been demonstrated repeatedly11,12. 
The biological activity of tachykinins, the 
neurotransmitters of the excitatory part of the 
nonadrenergic, noncholinergic (NANC) nervous 
system, depends on their interaction with three 
specific tachykinin receptors,  neurokinin (NK)1 
(specific for substance P), NK2 (specific for 
neurokinin A) and NK3 (specific for neurokinin B) 
receptors13-15. The adequate stimuli for tachykinin 
release from the sensory nerves in the airways are 
of chemical nature (especially those chemicals that 
are produced during inflammation and tissue 
damage). VIP, an anti-inflammatory neuropeptide, 
is a neurotransmitter of the inhibitory part of the 
NANC nervous system16.  
Peptidases are involved in the breakdown of 
neuropeptides17. Both neutral endopeptidase (NEP) 
and angiotensin converting enzyme (ACE) are 
involved in tachykinin breakdown18. NEP has been 
located to the airway mucosa and submucosa in 
contrast to ACE, which has been located in vascular 
cells. It has therefore been proposed that NEP is the 
main regulator of tachykinins in the airway, 
whereas ACE may influence tachykinins in the 
vascular space19. A decrease in NEP activity has 
been observed in response to substances which 
exacerbate asthma, such as smoking18. Smoking has 
also been found to promote the release of substance 
P (SP) from sensory nerves in addition to increasing 
NK1 and NK2 receptors in comparison to non-
smokers20. Therefore, smoking could potentially act 
as a pro-inflammatory stimulus that upregulates 
tachykinin activity in the airway, partly due to the 
decrease in NEP activity. Sont and coworkers21 
found that NEP expression was higher in the airway 
epithelium from asthmatic patients using inhaled 
corticosteroids compared with steroid-naïve 
asthmatic subjects, suggesting that NEP is 
upregulated by steroid use. It has therefore been 
postulated that NEP activity may have an important 
role in the regulation of tachykinin induced 
responses in human asthma18. 
 
Neuroimmune interaction in allergy  
Understanding the complex pathophysiology of 
allergic diseases has been a main challenge of 
clinical and experimental research for many years. 
During allergic inflammation, a bidirectional 
regulation of neuronal stimulation and allergic 
inflammation has been prospected. Neuromediators 
represent the key factor of this process, working on 
either immune or structural cells and exerting 
neuroimmunomodulatory functions5. Studies have 
demonstrated that in allergic inflammation, various 
cytokines, such as interleukin (IL)-1, mediate 
signals from the immune to the nervous system and 
stimulate neuromediator synthesis22. Vice versa, 
evidence has emerged that allergic inflammatory 
responses are controlled by neuromediators5,23. 
Therefore, signaling molecules that mediate 
inflammatory interactions among immune, 
neuronal, and structural cells (neuromediators) are 
becoming a focus of allergy research5. Because 
neuropeptides are short-lived signaling molecules 
that are rapidly degraded, their action is temporally 
limited and mainly restricted to the site of 
synthesis24. Neurotrophins, however, were found to 
be produced continuously during allergic 
inflammation. Thus, neuropeptides are considered 
to be the major initiators of allergic 
inflammation19,25, while neurotrophins might act as 
long-term modulators, amplifying inflammatory 
signals between the nervous and immune systems 
during allergic inflammation26,27. 
 
Sources of neuromediators in allergy: 
 Under physiological conditions, the 
primary sources of neuromediators are neuronal 
cells and nerve-associated cells, such as Schwann 
cells, glial cells, or fibroblasts28. During allergic 
inflammation, cells of the immune system and 
structural cells are able to express both the 
neuromediators and their corresponding 
receptors4,23. 
 
Neuromediators and immune cells: 
• Monocytes/macrophages: 
  Alveolar macrophages produce neurotrophins after 
allergen challenge29. Monocytes isolated from 
human peripheral blood showed a constitutive 
expression of neurotrophins in patients with allergy 
compared with those obtained from healthy 
donors30. 
• Eosinophils:  
Eosinophils are potentially able to express cell 
surface receptors for all neurotrophins, but receptor 
expression may depend on the level of maturation 
or activation level of these cells31. In one study, 
circulating blood eosinophils from patients with 
allergy did not show any Trk expression, but more 
importantly, eosinophils obtained from the 
bronchoalveolar lavage fluid (BALF) after allergen 
provocation expressed all neurotrophin receptors32.  
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• Lymphocytes:  
T lymphocytes have been shown to produce 
neuromediators, but the amount of synthesis 
depends on the activation level. T cells isolated 
from the inflamed lung showed high levels of 
BDNF synthesis, whereas T cells isolated from the 
spleen did not produce detectable BDNF. These 
differences may result from different T-cell 
populations in spleen and lung and/or a 
preactivation state of lung T cells at the site of local 
inflammation33.  
 
Neuromediators and structural cells: 
There is growing evidence that structural cells are 
actively involved in the local inflammatory 
response through synthesis of cytokines and other 
mediators28. Constitutive expression of many 
neuromediators in mouse lung epithelial cells is 
markedly upregulated after repeated allergen 
challenges in a murine model of experimental 
allergic asthma34. This finding indicates that the 
airway epithelium may be an important source for 
increased expression of some neuromediators in the 
allergic lung35. In the skin, keratinocytes are 
recognized as a primary source of some 
neuromediators during inflammatory conditions36. 
 
How neuromediators result in progression and 
amplification of allergic inflammation? 
A. Neuronal plasticity:  
Local overproduction of neurotrophins during 
allergic inflammation results in increased neuronal 
release of neuropeptides such as tachykinins, 
exhibiting a great degree of functional plasticity 
defined as neuronal plasticity (Fig. 2). The 
consequences are the development of neurogenic 
inflammation37,38. Neuropeptides released by 
sensory neurons then modulate a broad range of 
functional responses of immune cells including 
lymphocytes, eosinophils, mast cells, and 
macrophages, leading to activation and 
differentiation of these cells22,39. Immune cells 
contribute to this process by virtue of their 
neurotrophin expression. Therefore, neurotrophins 
can influence the intensity and duration of a local 
immune response either by direct signaling through 
specific neurotrophin receptors or through 




Figure 2. Neuronal plasticity mediated by neurotrophins. (Quoted from Renz et al., 2004)38 
 
 
B- Immunological plasticity:  
Neurotrophins act in autocrine as well as 
paracrine signaling. Because the pathophysiology 
of allergic diseases is characterized by the 
progression of allergic inflammation, the potential 
role of neurotrophins in progression and 
amplification of allergic inflammation is of a great 
interest. These effects are described by the term 
immunological plasticity that include 
enhancement of survival, differentiation, and/or 
proliferation of immune cells and activation of 
release of cytokines or mediators5. Therefore, 
neurogenic inflammation describes a vicious cycle 
of neuroimmune interactions that amplify allergic 
inflammation and neurotrophins are cross talks 
between immune and nervous systems in allergic 
inflammation22,38,39.  
Tissue mast cell numbers are dependent on factors 
controlling infiltration, local development, and 
survival in the tissues. An increase in mast cell 
numbers is a characteristic feature of the allergic 
inflammation40. Several studies have suggested 
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that NGF is involved in the development and 
maintenance of mast cell hyperplasia in the 
allergic airways41. In addition, NGF functions as a 
chemoattractant for mast cells41,42 and also 
supports the survival of mast cells as a cofactor 
together with stem cell factor43. Neuromediators 
also regulate mast cell degranulation and mediator 
release44. Abrogation of NGF signaling by 
intranasal application of neutralizing antibodies 
inhibits allergen induced early phase reaction, 
which is mediated by mast cell degranulation45.   
In addition, neurotrophins can directly stimulate 
lymphocytes to produce T-helper-2 (Th2) 
cytokines, going in line with the Th2 type shifted 
immune response. This is supported by studies in 
murine asthma models showing that treatment of 
mice with anti-NGF antibodies decreases the 
function of Th2 T-cells46. Th2 cells orchestrate 
many aspects of pathologic immune responses 
including effector functions of B-cells, mast cells 
and eosinophils. These cells produce an array of 
cytokines such as IL4, IL-5, IL-9 and IL-13. In B-
cells, IL-4 and IL-13 are involved in isotype 
switching towards IgE, while IL-5 possesses pro-
inflammatory properties, for example the 
development, differentiation, recruitment and 
survival of eosinophils47. So far, no information is 
available that neurotrophins directly influence the 
switch of naive CD41 T cells into Th2 cells. 
However, at least in a transgenic mouse model, 
NT-3 selectively supports the activity of antigen-
specific Th2 cells but not of Th1 cells because of 
an expression of the TrkC receptor on Th2 but not 
TH1 cells46.  
Neurotrophins also influence the developing 
immune response by acting as cytokines23. 
Moreover, in vitro studies have showed prolonged 
survival of BALF, but not blood eosinophils, by 
all members of mammalian neurotrophins due to 
their antiapoptotic effects32. Neurotrophin 
mediated survival of eosinophils (fig. 3) might 
contribute to the massive eosinophilia observed 
during asthma and it also contributes to increased 





BDNF: brain-derived neurotrophic factor; MCP: monocyte chemoattractant protein; NGF: nerve growth factor;  NT:  neurotrophins; 
VCAM-1: vascular cell adhesion molecule 1; VLA-4: very late antigen 4. 
 
Figure 3. Neurotrophins modulate biological effects of infiltrated eosinophils in the allergic airway. 
Within the inflamed tissue, expression of neurotrophins is increased. Eosinophils are then susceptible to 
neurotrophin-induced activation and survival. (Quoted from Nockher and Renz, 2006)27 
 
C- Angiogenesis and microvascular remodeling: 
 Angiogenesis encompasses the formation of 
vascular tissue from pre-existing vessels. 
Microvascular remodeling involves structural 
alterations of arterioles, capillaries, or venules 
without the formation of new vessels. Both are 
complex events that are regulated by a large number 
of mediators such as cytokines and growth factors48. 
Both angiogenesis and microvascular remodeling 
mainly result from endothelial cell proliferation and 
often occur simultaneously. It has been recognized 
that neurotrophins and tachykinins are vasoactive 
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factors affecting endothelial cell biology and elicit 
angiogenesis49. Moreover, it has been shown that 
NGF induces matrix metalloproteinase expression 
in vascular smooth muscle cells which contributes 
to the migratory response of smooth muscle cells by 
releasing them from their surrounding extracellular 
matrix after injury50,51.  
 
Neurogenic inflammation in some allergic 
diseases:  
Bronchial asthma  
Bronchial asthma is characterized by chronic 
airway inflammation, development of airway 
hyperreactivity (AHR), recurrent reversible airway 
obstruction and airway remodeling5. Bronchial 
asthma is more than an immunological disorder and 
both peripheral and central neural mechanisms are 
also involved in the pathogenesis of asthma52. It is 
now clear that inflammation and AHR do not 
develop independently from one another, but they 
are associated through a bidirectional signaling 
between cells of the immune and nervous systems. 
Therefore, the search for bidirectional signaling 
molecules between immune cells and neurons has 
become a novel focus regarding asthma research27.  
Neurotrophins are constitutively expressed by 
resident lung cells and are produced in increasing 
concentrations by immune cells invading the 
airways during allergic inflammation 38 (Fig. 4). 
Neurotrophins modify the functional activity of 
sensory and motor neurons, leading to enhanced 
and altered neuropeptide and tachykinin 
production38. Tachykinins interact in the airways 
with tachykinin NK1, NK2 and NK3 receptors to 
cause bronchoconstriction, plasma protein 
extravasation, and mucus secretion and to attract 
and activate immune cells. In preclinical studies, 
tachykinins have been implicated in the 
pathophysiology of asthma 53. 
 AHR, an important hallmark in the pathogenesis of 
asthma, may be defined as an increase in the ease 
and degree of airway narrowing in response to a 
wide range of bronchoconstrictor stimuli due to 
enhanced cholinergic activity54. Cholinergic 
activities were shown to be increased by 
tachykinins55,56. Neurotrophin- induced neuronal 
plasticity may induce AHR57 (Fig. 5). 
Neurotrophin-induced AHR may be the result of 
airway inflammation, as the infiltrating cells are 
capable of producing neurotrophins. NGF can 
induce AHR even without the background of 
inflammation, as NGF treatment of mice induced 
AHR. Thus, neurogenic inflammation describes a 
vicious cycle of neuroimmune interactions that 
amplify airway inflammation and AHR in allergic 
asthma22,39.  
NGF may be also involved in airway remodeling. 
Beside its effects on bronchial smooth muscle and 
hyperinnervation with sensory nerves, NGF induces 
fibroblast migration and differentiation into 
myofibroblasts, as well as collagen production58,59. 
Additionally, NGF plays a role in increased 
vascularisation by inducing endothelial cell and 
vascular smooth muscle cell proliferation and 
stimulating the release of proangiogenic factors60. 
 
Is there is a role for neurogenic inflammation in 
asthma in humans? 
Whilst there is convincing evidence of neurogenic 
inflammation in various animal models of asthma, 
the evidence in humans is less clear. Replication of 
the experimental approaches in humans has proven 
difficult with conflicting results. In terms of human 
studies, the three main investigative approaches 
have been: 
1. Studies to determine if pro-inflammatory 
neuropeptides and neurotrophins are elevated in the 
airways in asthma. 
2. Studies to examine different functional effects of 
neuropeptides and neurotrophins in asthma. 
3. Studies using inhibitors of pro-inflammatory 
neuropeptides to attempt to improve indices of 
asthma control in humans61.  
 
Atopic dermatitis and stress? How do emotions 
come into skin? 
Several common skin diseases are now 
acknowledged to be worsened by psychological 
stress, particularly immunodermatoses such as 
atopic dermatitis (AD), psoriasis, seborrheic 
eczema, prurigo nodularis, lichen planus, chronic 
urticaria and alopecia areata. AD is a chronic 
inflammatory skin disease associated with 
cutaneous hyperreactivity to environmental triggers, 
and is often the first step in the atopic march 
resulting in asthma and allergic rhinitis63. AD is a 
complex disease traditionally involving interaction 
of genetic, environmental, and immunologic 
factors. Recent studies suggest that psychoneuro-
immunologic factors and emotional stress are 
important in its evolution. The observations that 
external (psychologic) stressors may induce AD 
flares is explained by studies showing that stress 
impairs the skin barrier function and favors a shift 
in immunity toward a Th2 allergic response. 
Furthermore, patients with AD appear to have an 
inherited hypothalamic deficiency that impairs 
normal hypothalamic-pituitary-adrenal axis 
function. Psychologic and stress-reduction 
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interventions were recently shown to improve 
patient well-being, and to significantly improve 
cutaneous manifestations64. 
Mast cells play a key role in the development of 
inflammatory reaction to stress. Enhanced levels of 
neuropeptides released from nerve endings, resident 
cells (e.g.,  keratinocytes, fibroblasts, epidermal, 
dendritic and Langerhans cells) and immune cells 
influence the exacerbation of AD through 
enhancement of mast cell degranulation. This leads 
to the recruitment of inflammatory cells to the site 
of inflammation, vasodilatation and plasma 
extravasation, modulation of immunocyte function 
(e.g. mediator release from T-lymphocytes, 
induction of antibodies production from B cells and 
modulation of antigen presentation in Langerhans 
cells) and regulation of mediator release (cytokines, 
chemokines and growth factors). The epidermal 
keratinocytes are also affected by neurogenic 
inflammation (proliferation, apoptosis, spongiosis 
and edema). Modern biopsychosocial interventions 
can markedly benefit the well-being of AD patients, 
including improvement of skin manifestations (Fig. 
6). Various forms of relaxation therapy, 
biofeedback, autogenic training, massage therapy, 
and hypnosis have been used in treating 
dermatologic diseases. Although aimed at 
decreasing stress and anxiety, controlled studies of 
these interventions in AD have encountered 
contradictory results64,65.  
 
Allergic rhinosinusitis  
The nose is an air conditioner and is involved in the 
protection of the lower airways against inhalation of 
exogenous particles and airborne irritants. The nasal 
mucosa is therefore densely innervated by sensory 
nerves containing several neuropeptides66. In the 
airways, activation of sensory nerves leads to the 
release of multiple neuropeptides. In addition to 
their involvement in vasodilatation, plasma protein 
exudation and mucus secretion, sensory 
neuropeptides also participate in inflammatory cell 
recruitment. This neurogenic inflammation 
contributes to the intensity of nasal obstruction, 
rhinorrhea and headaches, the most common 
symptoms in chronic rhinosinusitis67. The 
concentration of neuropeptides is increased in the 
nasal mucosa of patients suffering from chronic 
rhinosinusitis. In contrast, the activity of the 
enzymes involved in the degradation of these 
sensory neuropeptides is markedly reduced. These 
observations should contribute to a better 
understanding of the pathophysiological 
mechanisms of one of the most frequently occurring 





ASM: airway smooth muscles; BDNF: brain-derived neurotrophic factor; Eos: eosinophils; Lym: lymphocytes; Mc: mast cells ;  Mo: 
monocytes; NGF: nerve growth factor;  NT-3:  neurotrophin-3. 
 
Figure 4. Production and effects of neurotrophins during allergic airway inflammation. (Quoted from 
Nockher and Renz, 2006)5 
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NGF, nerve growth factor 
 
Figure 5. Neurotrophins in asthma bronchiale. 
Inflammation derived neurotrophins such as NGF promote central features of allergic asthma. Neurotrophins induce 
neuropeptide production and neuronal hyperreactivity using a mechanism that is comparable to inflammatory pain. 
These events contribute to facilitated airway constriction (airway hyperreactivity). In addition, NGF can act directly as a 




Table 2. Some tachykinin receptors antagonists studies in humans. 
Name Inhibits Clinical Effect 
FK22494 NK1/ NK2 Inhibited bradykinin induced bronchoconstriction. 
No effect on NKA induced bronchoconstriction. 
CP-99,99495 NK1 No effect on lung function/ hypertonic saline bronchoconstriction. 
FK-88896 NK1 No effect on lung function / exercise induced bronchoconstriction 
(reduced recovery time). 
SR 4896897 NK2 Inhibited NKA induced bronchoconstriction 
No effect on lung function / AMP challenge. 
DNK33398 NK1/ NK2 Inhibited NKA induced bronchoconstriction. 
AVE588399 NK1/ NK2 Inhibited NKA induced bronchoconstriction 
No effect (? Potentiation of allergen induced late phase response). 






HPA axis: hypothalamic-pituitary-adrenal axis; Th: T-helper lymphocytes. 
 
Figure 6. Effects of stress on atopic dermatitis 
When the brain identifies an external perceived stressor, corticotropin- releasing hormone (CRH) is secreted from the 
hypothalamus, transported through the portal circulation to the pituitary, and induces adrenocorticotropic hormone 
release from the anterior pituitary into the general circulation. Simultaneous sympathetic nervous system activation 
results in glucocorticosteroid, catecholamine, and neuropeptide secretion. Catecholamines and cortisol have a potent 
effect on the immune system. They mediate differentiation of naive T helper cells toward Th2 phenotype. This tilts the 
balance toward humoral immunity by increasing production of IL-4, IL-5, and IL-13; these activate B-cells, mast cells, 
and eosinophils, increasing the allergic inflammatory response, and exacerbating Th2-mediated diseases involving these 
pathways. Additionally, cutaneous neuropeptides (egg, substance P ) stimulate mast cells and mediate AD deterioration. 
Another known effect of stress is disruption of the skin barrier function, leading to increased infections and possibly 
enhanced cutaneous penetration of allergens. (Quoted from Arndt et al., 2008)64 
 
Ocular allergy 
Ocular allergy is a common disorder affecting 20% 
of the population in developing countries. Ocular 
allergy comprises the acute (self-limiting) type-I 
hypersensitivity seasonal and perennial allergic 
conjunctivitis and the more complex, chronic and 
severe forms of atopic and vernal 
keratoconjunctivitis, and giant papillary 
conjunctivitis. Disease severity can range from mild 
itching and redness to the more serious vision 
threatening forms affecting the cornea68. As a recent 
point of view, during allergic states, several 
neuromediators are released from intracellular sites 
or their expression is changed. They drive the 
common signs of ocular allergic inflammation 
(pain, redness, swelling, heat), by acting directly on 
cells responsible for both early and late phase 
reactions as well as on epithelial cells and 
fibroblasts, leading to either self-limiting or 
chronicity states. In allergic conjunctivitis, the main 
mediator is histamine which is a vasoactive peptide 
that drives vasodilation, vascular permeability, cell 
proliferation, tissue growth and repair69. SP and 
NGF may drive histamine release from mast 
cells70,71.  
 
Neurogenic inflammation and allergy in clinical 
practice 
 
1- Assessment  of the severity of inflammation in 
some allergic diseases 
Bronchoalveolar lavage, sputum and peripheral 
blood samples have been used to assess the 
presence of neuromediators and their receptors in 
allergic diseases61. In clinical practice, assessment 
of airway inflammation is difficult. Therefore, 
detection of biological markers of airway 
inflammation might offer help for proper 
monitoring of asthma severity for better 
management of this disease72. Sputum BDNF and 
serum CGRP levels were reported to be up-
regulated during acute asthma exacerbations and 
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their levels positively correlated with eosinophil 
numbers in sputum and blood, respectively73,74. A 
recent study75 conducted on 24 Egyptian children 
and adolescents during and after acute asthma 
exacerbations demonstrated that sputum NKA 
levels were up-regulated during acute asthma 
exacerbations and they positively correlated with 
exacerbation severity.  
 
2-Therapeutic applications  
Neurotrophin antagonism: 
Neurotrophin antagonism for asthma therapy has 
not been tested in humans so far. However, there 
are now a number of highly specific antagonists 
under development76-79 only tested in animal models 
of asthma80. Several pharmacological strategies 
were used in animal models of asthma:  
1. Direct blocking of neurotrophins by 
antibodies45,81,82.  
2. Blocking the high affinity receptors Trks by 
decoy or antibodies83. 
3. Blocking the low affinity panneurotrophin 
receptor p75NTR by antibodies84. 
4. Blocking neurotrophin signal transduction by 
tyrosine kinase inhibitors like K252a or tyrphostin 
AG87985. 
These experiments demonstrated that blocking of 
neurotrophins or their receptors is able to inhibit the 
development of the key characteristics of asthma in 
preclinical models (mouse, rat and guinea pig). 
Blocking neurotrophins diminished the main 
features of human asthma like airway inflammation, 
airway hyperreactivity and allergen specific early 
phase response70,86,87. However, there are 
considerable concerns about the use of neurotrophin 
antagonists in human asthma. Neurotrophins are 
highly potent factors involved in many essential 
physiological conditions, especially in the central 
nervous system, where they can induce long lasting 
alterations. Thus, a careful balance with respect to 
the expected beneficial pharmacological actions in 
comparison to the possible side effects is essential. 
Since asthma has several effective conventional 
treatment options like steroids, the use of 
neurotrophin antagonists is critical for the treatment 
of asthma. However, there are patient subgroups 
with severe, difficult to treat asthma that might 
benefit from new therapeutic options62. 
 
Neuropeptides antagonism: 
A number of strategies are possible to interfere with 
the action of sensory neuropeptides in the airways: 
that include:  
1. Depletion of neuropeptides within nerves [e.g. by 
the neurotoxin capsaicin]. 
2. Inhibition of the release of sensory neuropeptides 
[e.g. by β2-adrenoceptor agonist, theophylline, 
cromoglycate or phosphodiesterase (PDE4) 
inhibitors]. 
3. Inhibition of tachykinin receptors by receptor 
antagonists. A number of receptor antagonists have 
been used such as dual NK1/NK2 or triple 
NK1/NK2/NK3 tachykinin receptor antagonists88 
(table 2), but they seem unlikely to confer any 
additional benefit to inhaled steroid therapy in 
humans. This is in contrast to the extensive and 
overwhelming data suggesting a role for 
tachykinins in asthma. There are several 
explanations for this apparent paradox89,90: 
a. The lack of efficacy can be easily explained by 
the low potency or defective pharmacokinetics of 
the compounds tested so far. Potent tachykinin 
receptor antagonists have not been considered for 
application in airways diseases, but for depression 
or emesis91. 
b. Blocking either NK1 or NK2 receptor is probably 
an insufficient approach, as most of the effects of 
tachykinins in the airways are mediated by more 
than one tachykinin receptor. 
c. In the application of a new tachykinin receptor 
antagonist to airway diseases, it is crucial that one 
first demonstrates that the antagonist is indeed able 
to block airway effects of an agonist (e.g. SP or 
neurokinin A). This allows to determine the in vivo 
activity of the antagonist under consideration and to 
determine dose and dosing frequency for further 
clinical study. 
Once a potent drug is identified, that can be 
administered twice, or preferably once a day, 
clinical studies are to be conducted to define the 
potential therapeutic benefit in either asthma or 
chronic obstructive pulmonary disease. These 
clinical studies will need to last for at least 3, 
preferably 6 or 12 months, in order to demonstrate 
changes in relevant clinical outcomes. This is 
especially important to detect a possible effect on 
exacerbations of asthma or chronic obstructive 
pulmonary disease, situations where a release of 
tachykinins from human airway tissue has been 
suggested to occur92,93.  
 
Key Messages  
Tissue and immune cells produce and respond to 
neuromediators. Studies of various allergic 
diseases performed over the period of the last 2 
decades indicate that neuromediators are 
upregulated in allergic diseases such as bronchial 
asthma and atopic dermatitis and may act as 
inflammatory cytokines. There is a growing 
evidence that neuromediators are part of an 
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integrated adaptive response to several offending 
stimuli that connect cells of the immune and 
nervous system together with structural cells. On 
the basis of these observations, a more intense 
investigation of the complex biological functions of 
neuromediators might open new opportunities for 
the development of novel therapeutic intervention 
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